SkinCeuticals' Discoloration Defense is clinically proven to reduce the appearance of dark spots and discoloration on the face. Powered by kojic acid, tranexamic acid, and vitamin B3, this advanced formula is a hydroquinone-free skin brightening serum.

Clinical Studies:
In a 12-week clinical study*, Discoloration Defense significantly improved the appearance of key skin discoloration markers on Fitzpatrick I-IV skin tones:

60% average improvement in the appearance of stubborn brown patches
59% average improvement in the appearance of skin discoloration
81% average improvement in the appearance of post-acne marks
59% average improvement in the appearance of even skin tone

In a 12-week study** on deeper skin tones (Fitzpatrick V-VI), twice-daily application of Discoloration Defense demonstrated a statistically-significant improvement in the appearance of discoloration, post-inflammatory discoloration, and even skin tone:

33% reduction in hyperpigmentation at 12 weeks
34% reduction in post-inflammatory hyperpigmentation at 12 weeks

CLINICALLY PROVEN RESULTS
Individual results at 12 weeks.

Before and after results
Protocol:
12-week, clinical study, 63 subjects. Discoloration Defense Serum was applied to the face twice a day in conjunction with a sunscreen

*A 12-week, single-center, clinical study was conducted on 50 females, ages 25 to 60, Fitzpatrick I-IV, with mild-to-moderate facial skin discoloration, including stubborn dark spots, post-acne marks and uneven skin tone. Discoloration Defense was applied to the face twice a day in conjunction with a sunscreen. Efficacy and tolerability evaluations were conducted at baseline and at weeks 2, 4, 8, and 12.

**A 12-week, single-center, clinical study was conducted on 51 female subjects, Fitzpatrick V-VI, with visible signs of skin discoloration/hyperpigmentation, including post-inflammatory hyperpigmentation and melasma. Discoloration Defense was applied to the face twice a day in conjunction with a sunscreen. Efficacy and tolerability evaluations were conducted at baseline and at weeks 2, 4, 8, and 12.

Front Page